Clinical Trial Update: IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC) [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating IBI110 with sintilimab for second-line advanced or metastatic esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• IBI110 (IBI110)
• Sintilimab (sintilimab)

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Esophageal Squamous Cell Carcinoma (ESCC), PD-1 Inhibitors | Phase 2 | Status: UNKNOWN